Toxin-induced hyperthermic syndromes

Medical Clinics of North America

Volumn 89, Issue 6, 2005, Pages 1277-1296

  Rusyniak, Daniel E ^a,b   Sprague, Jon E ^c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CARVEDILOL; CHLORPROMAZINE; CYPROHEPTADINE; DANTROLENE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; IPRONIAZID; LEVODOPA; LITHIUM; METHYSERGIDE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PETHIDINE; PROCHLORPERAZINE; PROMETHAZINE; PROPRANOLOL DERIVATIVE; RISPERIDONE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

BODY TEMPERATURE; CATATONIA; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DYSKINESIA; ERYTHEMA; ERYTHROMELALGIA; HUMAN; HYPERTHERMIA; HYPOTENSION; LIVER DISEASE; LIVER TOXICITY; MALIGNANT HYPERTHERMIA; MUSCLE WEAKNESS; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN SYNDROME; THERMOGENESIS; WITHDRAWAL SYNDROME;

ANESTHESIA, GENERAL; BODY TEMPERATURE REGULATION; HUMANS; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; SYNDROME; TOXINS, BIOLOGICAL;

EID: 26844569490     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2005.06.002     Document Type: Review

References (142)

1. K.O. Adubofour, G.T. Kajiwara, and C.M. Goldberg Oxybutynin-induced heatstroke in an elderly patient Ann Pharmacother 30 2 1996 144 147
2. B.B. Lowell, and B.M. Spiegelman Towards a molecular understanding of adaptive thermogenesis Nature 404 6778 2000 652 660
3. N. Charkoudian Skin blood flow in adult human thermoregulation: how it works, when it does not, and why Mayo Clin Proc 78 5 2003 603 612
4. B. Nielsen Heat acclimation - mechanisms of adaptation to exercise in the heat Int J Sports Med 19 Suppl 2 1998 S154 S156
5. J. De Witte, and D.I. Sessler Perioperative shivering: physiology and pharmacology Anesthesiology 96 2 2002 467 484
6. B.N. Mallick, S.K. Jha, and F. Islam Presence of alpha-1 adrenoreceptors on thermosensitive neurons in the medial preoptico-anterior hypothalamic area in rats Neuropharmacology 42 5 2002 697 705
7. B. Cox, and T.F. Lee Further evidence for a physiological role for hypothalamic dopamine in thermoregulation in the rat J Physiol 300 1980 7 17
8. N.J. Rothwell CNS regulation of thermogenesis Crit Rev Neurobiol 8 1-2 1994 1 10
9. L. Landsberg, M.E. Saville, and J.B. Young Sympathoadrenal system and regulation of thermogenesis Am J Physiol 247 2 Pt 1 1984 E181 E189
10. K.B. Wallace, and A.A. Starkov Mitochondrial targets of drug toxicity Annu Rev Pharmacol Toxicol 40 2000 353 388
11. O. Boss, P. Muzzin, and J.P. Giacobino The uncoupling proteins, a review Eur J Endocrinol 139 1 1998 1 9
12. D.G. Nicholls, and R.M. Locke Thermogenic mechanisms in brown fat Physiol Rev 64 1 1984 1 64
13. O. Boss, S. Samec, and A. Paoloni-Giacobino Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression FEBS Lett 408 1 1997 39 42
14. R.A. Simonyan, M. Jimenez, and R.B. Ceddia Cold-induced changes in the energy coupling and the UCP3 level in rodent skeletal muscles Biochim Biophys Acta 1505 2-3 2001 271 279
15. M.O. Ribeiro, F.L. Lebrun, and M.A. Christoffolete Evidence of UCP1-independent regulation of norepinephrine-induced thermogenesis in brown fat Am J Physiol Endocrinol Metab 279 2 2000 E314 E322
16. D.W. Gong, Y. He, and M. Karas Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta 3-adrenergic agonists, and leptin J Biol Chem 272 39 1997 24129 24132
17. A. Rubio, A. Raasmaja, and A.L. Maia Effects of thyroid hormone on norepinephrine signaling in brown adipose tissue. I. Beta 1- and beta 2-adrenergic receptors and cyclic adenosine 3′,5′-monophosphate generation Endocrinology 136 8 1995 3267 3276
18. A.C. Bianco, S.D. Carvalho, and C.R. Carvalho Thyroxine 5′-deiodination mediates norepinephrine-induced lipogenesis in dispersed brown adipocytes Endocrinology 139 2 1998 571 578
19. J.E. Silva Thyroid hormone control of thermogenesis and energy balance Thyroid 5 6 1995 481 492
20. M.L. Reitman, Y. He, and D.W. Gong Thyroid hormone and other regulators of uncoupling proteins Int J Obes Relat Metab Disord 23 Suppl 6 1999 S56 S59
21. J.R. Roberts, E. Quattrocchi, and M.A. Howland Severe hyperthermia secondary to intravenous drug abuse Am J Emerg Med 2 4 1984 373
22. W.C. Kendrick, A.R. Hull, and J.P. Knochel Rhabdomyolysis and shock after intravenous amphetamine administration Ann Intern Med 86 4 1977 381 387
23. M.D. Ginsberg, M. Hertzman, and W.W. Schmidt-Nowara Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke Ann Intern Med 73 1 1970 81 85
24. K.J. Dar, and M.E. McBrien MDMA induced hyperthermia: report of a fatality and review of current therapy Intensive Care Med 22 9 1996 995 996
25. F.H. Prior, G.K. Isbister, and A.H. Dawson Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine Med J Aust 176 5 2002 240 241
26. R.A. Bodner, T. Lynch, and L. Lewis Serotonin syndrome Neurology 45 2 1995 219 223
27. M.J. Eadie Convulsive ergotism: epidemics of the serotonin syndrome? Lancet Neurol 2 7 2003 429 434
28. L.R. Caporael Ergotism: the satan loosed in Salem? Science 192 4234 1976 21 26
29. R.S. Mitchell Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis Ann Intern Med 42 1955 417 424
30. D.A. Asch, and R.M. Parker The Libby Zion case. One step forward or two steps backward? N Engl J Med 318 12 1988 771 775
31. K.C. Mills Serotonin syndrome. A clinical update Crit Care Clin 13 4 1997 763 783
32. H. Sternbach The serotonin syndrome Am J Psychiatry 148 6 1991 705 713
33. S.E. Hilton, H. Maradit, and H.J. Moller Serotonin syndrome and drug combinations: focus on MAOI and RIMA Eur Arch Psychiatry Clin Neurosci 247 3 1997 113 119
34. J.W. Radomski, S.M. Dursun, and M.A. Reveley An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria Med Hypotheses 55 3 2000 218 224
35. C.M. Milroy, J.C. Clark, and A.R. Forrest Pathology of deaths associated with "ecstasy" and "eve" misuse J Clin Pathol 49 2 1996 149 153
36. L.R. Gowing, S.M. Henry-Edwards, and R.J. Irvine The health effects of ecstasy: a literature review Drug Alcohol Rev 21 1 2002 53 63
37. P.J. Mason, V.A. Morris, and T.J. Balcezak Serotonin syndrome. Presentation of 2 cases and review of the literature Medicine 79 4 2000 201 209
38. P. Kolecki Isolated venlafaxine-induced serotonin syndrome J Emerg Med 15 4 1997 491 493
39. M. Lejoyeux, F. Fineyre, and J. Ades The serotonin syndrome Am J Psychiatry 149 10 1992 1410 1411
40. B.P. Skop, J.A. Finkelstein, and T.R. Mareth The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease Am J Emerg Med 12 6 1994 642 644
41. D. Meyer, and V. Halfin Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review J Clin Psychopharmacol 1 5 1981 319 321
42. R. Sandyk L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine J Clin Psychopharmacol 6 3 1986 194 195
43. R. Mahlberg, D. Kunz, and J. Sasse Serotonin syndrome with tramadol and citalopram Am J Psychiatry 161 6 2004 1129
44. E.C. Muly, W. McDonald, and D. Steffens Serotonin syndrome produced by a combination of fluoxetine and lithium Am J Psychiatry 150 10 1993 1565
45. J.E. Malberg, and L.S. Seiden Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat J Neurosci 18 13 1998 5086 5094
46. S.F. Ali, G.D. Newport, and R.R. Holson Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice Brain Res 658 1-2 1994 33 38
47. D.B. Miller, and J.P. O'Callaghan Elevated environmental temperature and methamphetamine neurotoxicity Environ Res 92 1 2003 48 53
48. C.J. Gordon, W.P. Watkinson, and J.P. O'Callaghan Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat Pharmacol Biochem Behav 38 2 1991 339 344
49. P.M. Marzuk, K. Tardiff, and A.C. Leon Ambient temperature and mortality from unintentional cocaine overdose JAMA 279 22 1998 1795 1800
50. J.A. Duarte, A. Leao, and J. Magalhaes Strenuous exercise aggravates MDMA-induced skeletal muscle damage in mice Toxicology 206 3 2005 349 358
51. M. Harding, and D.I. Peterson The effect of exercise and limitation of movement on amphetamine toxicity J Pharmacol Exp Ther 145 1963 47 51
52. D.E. Rusyniak, S.L. Tandy, and S.K. Hekmatyar The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine mediated skeletal muscle hyperthermia and rhabdomyolysis J Pharmacol Exp Ther 313 2 2005 629 639
53. J.A. Henry, K.J. Jeffreys, and S. Dawling Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") Lancet 340 8816 1992 384 387
54. J.E. Sprague, R.E. Brutcher, and E.M. Mills Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with alpha1- plus beta3-adrenoreceptor antagonists Br J Pharmacol 142 4 2004 667 670
55. C.P. Stephenson, G.E. Hunt, and A.N. Topple The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain Neuroscience 92 3 1999 1011 1023
56. K. Nisijima, K. Shioda, and T. Yoshino Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome Neurochem Int 43 2 2003 155 164
57. K. Nisijima, T. Yoshino, and T. Ishiguro Risperidone counteracts lethality in an animal model of the serotonin syndrome Psychopharmacology (Berl) 150 1 2000 9 14
58. K. Shioda, K. Nisijima, and T. Yoshino Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine Prog Neuropsychopharmacol Biol Psychiatry 28 4 2004 633 640
59. K. Nisijima, M. Nibuya, and H. Sugiyama Abnormal CSF monoamine metabolism in serotonin syndrome J Clin Psychopharmacol 23 5 2003 528 531
60. K. Nisijima Abnormal monoamine metabolism in cerebrospinal fluid in a case of serotonin syndrome J Clin Psychopharmacol 20 1 2000 107 108
61. F. Fernandez, S. Aguerre, and P. Mormede Influences of the corticotropic axis and sympathetic activity on neurochemical consequences of 3,4-methylenedioxymethamphetamine (MDMA) administration in Fischer 344 rats Eur J Neurosci 16 4 2002 607 618
62. J.E. Sprague, M.L. Banks, and V.J. Cook Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy) J Pharmacol Exp Ther 305 1 2003 159 166
63. J.E. Sprague, N.M. Mallett, and D.E. Rusyniak UCP3 and thyroid hormone involvement in methamphetamine-induced hyperthermia Biochem Pharmacol 68 7 2004 1339 1343
64. T. Makisumi, K. Yoshida, and T. Watanabe Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism Eur J Pharmacol 363 2-3 1998 107 112
65. J.E. Sprague, P. Moze, and D. Caden Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model Crit Care Med 33 6 2005 1311 1316
66. H.J. Stuerenburg, K. Petersen, and T. Baumer Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users Neuro Endocrinol Lett 23 3 2002 259 261
67. N.P. Pedersen, and W.W. Blessing Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits J Neurosci 21 21 2001 8648 8654
68. C.G. Crandall, W. Vongpatanasin, and R.G. Victor Mechanism of cocaine-induced hyperthermia in humans Ann Intern Med 136 11 2002 785 791
69. J. Zhao, B. Cannon, and J. Nedergaard Alpha1-adrenergic stimulation potentiates the thermogenic action of beta3-adrenoreceptor-generated cAMP in brown fat cells J Biol Chem 272 52 1997 32847 32856
70. E.M. Mills, D.E. Rusyniak, and J.E. Sprague The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine J Mol Med 82 12 2004 787 799
71. E.M. Mills, M.L. Banks, and J.E. Sprague Uncoupling the agony from ecstasy Nature 426 2003 403 404
72. K. Nisijima, T. Yoshino, and K. Yui Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome Brain Res 890 1 2001 23 31
73. A.O. Mechan, B. Esteban, and E. O'Shea The pharmacology of the acute hyperthermic response that follows administration of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy") to rats Br J Pharmacol 135 1 2002 170 180
74. D. Van Oekelen, A. Megens, and T. Meert Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats Behav Pharmacol 13 4 2002 313 318
75. W.W. Blessing, B. Seaman, and N.P. Pedersen Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats J Neurosci 23 15 2003 6385 6391
76. D.E. Rusyniak, M.L. Banks, and E.M. Mills Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia Anesthesiology 101 1 2004 263 [author reply: 264]
77. C. Singarajah, and N.G. Lavies An overdose of ecstasy. A role for dantrolene Anaesthesia 47 8 1992 686 687
78. J.D. Watson, C. Ferguson, and C.J. Hinds Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 48 12 1993 1057 1060
79. C. Webb, and V. Williams Ecstasy intoxication: appreciation of complications and the role of dantrolene Anaesthesia 48 6 1993 542 543
80. A. Graudins, A. Stearman, and B. Chan Treatment of the serotonin syndrome with cyproheptadine J Emerg Med 16 4 1998 615 619
81. R.I. Lappin, and E.L. Auchincloss Treatment of the serotonin syndrome with cyproheptadine N Engl J Med 331 15 1994 1021 1022
82. P.K. Gillman The serotonin syndrome and its treatment J Psychopharmacol 13 1 1999 100 109
83. W.H. Vogel, J. Miller, and K.H. DeTurck Effects of psychoactive drugs on plasma catecholamines during stress in rats Neuropharmacology 23 9 1984 1105 1108
84. E.G. Zalis, G.D. Lundberg, and G. Kaplan The effect of extracorporeal cooling on amphetamine toxicity Arch Int Pharmacodyn Ther 159 1 1966 189 195
85. E. Hadad, M. Rav-Acha, and Y. Heled Heat stroke: a review of cooling methods Sports Med 34 8 2004 501 511
86. Y.T. Chou, S.T. Lai, and C.C. Lee Hypothermia attenuates circulatory shock and cerebral ischemia in experimental heatstroke Shock 19 4 2003 388 393
87. M. Khan, and D. Farver Recognition, assessment and management of neuroleptic malignant syndrome S D J Med 53 9 2000 395 400
88. J. Ananth, S. Parameswaran, and S. Gunatilake Neuroleptic malignant syndrome and atypical antipsychotic drugs J Clin Psychiatry 65 4 2004 464 470
89. M.V. Balzan The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity Postgrad Med J 74 868 1998 72 76
90. J.R. Carbone The neuroleptic malignant and serotonin syndromes Emerg Med Clin North Am 18 2000 317 325
91. S.N. Caroff, and S.C. Mann Neuroleptic malignant syndrome Med Clin North Am 77 1 1993 185 202
92. D. Nierenberg, M. Disch, and E. Manheimer Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome Clin Pharmacol Ther 50 5 Pt 1 1991 580 586
93. P. Rosebush, and T. Stewart A prospective analysis of 24 episodes of neuroleptic malignant syndrome Am J Psychiatry 146 6 1989 717 725
94. G. Oppenheim Mutism and hyperthermia in a patient treated with neuroleptics Med J Aust 2 5 1973 228 229
95. V.R. Velamoor, R.M.G. Norman, and S.N. Caroff Progression of symptoms in neuroleptic malignant syndrome J Nerv Ment Dis 182 1994 168 173
96. P.I. Rosebush, and M.F. Mazurek Serum iron and neuroleptic malignant syndrome Lancet 338 8760 1991 149 151
97. L.S. Friedman, L.A. Weinrauch, and J.A. D'Elia Metoclopramide-induced neuroleptic malignant syndrome Arch Intern Med 147 8 1987 1495 1497
98. G.R. Pesola, and C. Quinto Prochlorperazine-induced neuroleptic malignant syndrome J Emerg Med 14 6 1996 727 729
99. K.M. Chan-Tack Neuroleptic malignant syndrome due to promethazine South Med J 92 10 1999 1017 1018
100. C. Rainer, N.A. Scheinost, and E.J. Lefeber Neuroleptic malignant syndrome. When levodopa withdrawal is the cause Postgrad Med 89 5 1991 175 178 180
101. T.R. Olmsted Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics South Med J 81 7 1988 888 891
102. V.W. Henderson, and G.F. Wooten Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 31 2 1981 132 137
103. R.J. Gurrera Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome Am J Psychiatry 156 2 1999 169 180
104. K. Nisijima, K. Oyafuso, and T. Shimada Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy Biol Psychiatry 39 5 1996 383 384
105. J.H. Feibel, and R.B. Schiffer Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report Am J Psychiatry 138 8 1981 1115 1116
106. R.J. Gurrera, and J.A. Romero Sympathoadrenomedullary activity in the neuroleptic malignant syndrome Biol Psychiatry 32 4 1992 334 343
107. B. Spivak, D.I. Maline, and Y. Vered Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome Acta Psychiatr Scand 102 3 2000 226 230
108. S. Dhib-Jalbut, R. Hesselbrock, and M.M. Mouradian Bromocriptine treatment of neuroleptic malignant syndrome J Clin Psychiatry 48 2 1987 69 73
109. A. Janati, and R.T. Webb Successful treatment of neuroleptic malignant syndrome with bromocriptine South Med J 79 12 1986 1567 1571
110. W.M. Verhoeven, A. Elderson, and H.G. Westenberg Neuroleptic malignant syndrome: successful treatment with bromocriptine Biol Psychiatry 20 6 1985 680 684
111. C. Bismuth, P. de Rohan-Chabot, and M. Goulon Dantrolene - a new therapeutic approach to the neuroleptic malignant syndrome Acta Neurol Scand Suppl 100 1984 193 198
112. P. Sakkas, J.M. Davis, and P.G. Janicak Drug treatment of the neuroleptic malignant syndrome Psychopharmacol Bull 27 3 1991 381 384
113. P.I. Rosebush, T. Stewart, and M.F. Mazurek The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 159 1991 709 712
114. T.J. Schvehla, and M. Herjanic Neuroleptic malignant syndrome, bromocriptine, and anticholinergic drugs J Clin Psychiatry 49 7 1988 283 284
115. V.R. Velamoor, G.N. Swamy, and R.S. Parmar Management of suspected neuroleptic malignant syndrome Can J Psychiatry 40 9 1995 545 550
116. T.Y. Lew, and G. Tollefson Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam Biol Psychiatry 18 12 1983 1441 1446
117. H. Miyaoka, K. Shishikura, and T. Otsubo Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry 154 6 1997 882
118. V.P. Kontaxakis, G.N. Christodoulou, and M.P. Markidis Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam Acta Psychiatr Scand 78 3 1988 396 398
119. Y. Sato, T. Asoh, and N. Metoki Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease J Neurol Neurosurg Psychiatry 74 5 2003 574 576
120. P.I. Rosebush, T.D. Stewart, and A.J. Gelenberg Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients J Clin Psychiatry 50 8 1989 295 298
121. M.A. Denborough, and R.R.H. Lovell Anaesthetic deaths in a family Lancet 2 1960 45
122. M. Denborough Malignant hyperthermia Lancet 9134 352 1998 1131 1136
123. J. Loke, and D.H. MacLennan Malignant hyperthermia and central core disease: disorders of Ca2+ release channels Am J Med 104 5 1998 470 486
124. P.M. Hopkins Malignant hyperthermia: advances in clinical management and diagnosis Br J Anaesth 85 1 2000 118 128
125. M. Naguib, and M.M. Magboul Adverse effects of neuromuscular blockers and their antagonists Drug Saf 18 2 1998 99 116
126. J.R. Tobin, D.R. Jason, and V.R. Challa Malignant hyperthermia and apparent heat stroke JAMA 286 2 2001 168 169
127. F. Wappler, M. Fiege, and M. Steinfath Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis Anesthesiology 94 1 2001 95 100
128. S.J. Kaus, and M.A. Rockoff Malignant hyperthermia Pediatr Clin North Am 41 1 1994 221 237
129. J. Haggendal, L. Jonsson, and J. Carlsten The role of sympathetic activity in initiating malignant hyperthermia Acta Anaesthesiol Scand 34 8 1990 677 682
130. C.H. Williams, S.E. Dozier, and W. Buzello Plasma levels of norepinephrine and epinephrine during malignant hyperthermia in susceptible pigs J Chromatogr 344 1985 71 80
131. D. Lister, G.M. Hall, and J.N. Lucke Porcine malignant hyperthermia. III. Adrenergic blockade Br J Anaesth 48 9 1976 831 838
132. J.N. Lucke, H. Denny, and G.M. Hall Porcine malignant hyperthermia. VI. The effects of bilateral adrenalectomy and pretreatment with bretylium on the halothane-induced response Br J Anaesth 50 3 1978 241 246
133. R.M. Maccani, D.J. Wedel, and R.E. Hofer Norepinephrine does not potentiate porcine malignant hyperthermia Anesth Analg 82 4 1996 790 795
134. C. Gerdes, A. Richter, and R. Annies Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs Eur J Pharmacol 220 1 1992 91 94
135. W. Loscher, U. Witte, and G. Fredow Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia Naunyn Schmiedebergs Arch Pharmacol 341 6 1990 483 493
136. M. Fiege, F. Wappler, and R. Weisshorn Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy") Anesthesiology 99 5 2003 1132 1136
137. M.U. Gerbershagen, F. Wappler, and M. Fiege Effects of a 5HT(2) receptor agonist on anaesthetized pigs susceptible to malignant hyperthermia Br J Anaesth 91 2 2003 281 284
138. W. Loscher, C. Gerdes, and A. Richter Lack of prophylactic or therapeutic efficacy of 5-HT2A receptor antagonists in halothane-induced porcine malignant hyperthermia Naunyn Schmiedebergs Arch Pharmacol 350 4 1994 365 374
139. A. Ward, M.O. Chaffman, and E.M. Sorkin Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity Drugs 32 2 1986 130 168
140. T.E. Nelson, M. Lin, and G. Sapata-Sudo Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel: clinical implications Anesthesiology 84 6 1996 1368 1379
141. K. Jurkat-Rott, T. McCarthy, and F. Lehmann-Horn Genetics and pathogenesis of malignant hyperthermia Muscle Nerve 23 1 2000 4 17
142. D.J. Wedel, J.G. Quinlan, and P.A. Iaizzo Clinical effects of intravenously administered dantrolene Mayo Clin Proc 70 3 1995 241 246